Table 2 Treatment response to pembrolizumab or nivolumab
From: Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
|  | Pembrolizumab (n = 25) | Nivolumab (n = 95) | P value |
|---|---|---|---|
Partial response | 2 (8.0%) | 7 (7.4%) | 0.90 |
Stable disease | 9 (36.0%) | 30 (31.6%) | Â |
Progressive disease | 14 (56.0%) | 58 (61.0%) | Â |
Disease control rate | 11 (44.0%) | 37 (39.0%) | Â |